D.E. Shaw & Co’s Legend Biotech LEGN Stock Holding History

D.E. Shaw & Co’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,100	Closed	-$309K	–	4549
2025 Q1	$309K	Hold	9,100	–	–	﹤0.01%	3748
2024 Q4	$296K	Buy	+9,100	New	+$377K	﹤0.01%	3893

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

D.E. Shaw & Co's LEGN Position: Q2 2024 in Review

D.E. Shaw & Co sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 40,922 shares — an estimated $2.3M sold.

D.E. Shaw & Co first reported a position in LEGN in Q2 2021 and held it in 12 quarters. The position peaked at $20.9M in Q3 2022. 180 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

D.E. Shaw & Co reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
D.E. Shaw & Co sold 40,922 Legend Biotech shares in Q2 2024, an estimated $2.3M.
D.E. Shaw & Co first reported a position in Legend Biotech in Q2 2021 and held it in 12 quarters.
D.E. Shaw & Co's Legend Biotech position peaked at $20.9M in Q3 2022.
180 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.